Company Overview and News
Earlier this year, I initiated active coverage of GAIN (8.2% yield) and its preferred stocks GAINM (6.2% yield) and now its newly issued GAINL (6.3% yield).
AIY AINV CLA GAIN GAINM MCQ KAP PNNT BKCC MCV PFLT OSLE GADDP GAINL GLADO HTGZ KCAP GLAD ABDC MSCA CPTA MCC TCRX ARCC HCAPL FSIC MAIN TCPC AIB TCRD TCRZ PSEC HTGX NMFC HTGY TSLF OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA
I recently purchased additional shares of this higher quality BDC that's trading 6% below book value paying a 9% dividend yield with an upcoming special dividend in Q4.
AIY AINV CLA MCQ KAP PNNT BKCC MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC CPTA MCC TCRX ARCC HCAPL FSIC TCPC AIB TCRD TCRZ PSEC HTGX NMFC TSLF HTGY OCSI ARU OCSL MCX HCAP SUNS HTGC PBB PNTA
Part 2 of this article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK MDLY NEWTL PBB
WallStars are distinguished by positive broker target price upsides. Five top net-gain financial WallStars, MDLY, BLX, GARS, CPTA, and BBVA averaged 42.29% estimated net gains per one-year targets as of September 7, 2018.
AIY CMFN TCRX AINV GARS CLA FSIC AIC GECC TCPC BVA AIB TCRD TCRZ TSLF AI OFS MDLY CPTA AIW
The Indian benchmark indices are trading on a negative note this Monday morning with the Nifty50 trading at 11,530, down 58 points while the Sensex is trading lower by 193 points at 38,196.
500325 HCTHY PRMQY 511389 533179 CADILAHC 532400 KPIT USHAMART 532321 532281 RLNIY GICHSGFIN BPCL AXB FSIC UHBTY YYBKY 511676 ALBERTDA JSWSTEEL AXBA 533638 BRQPY HCLTECH TCS HINDPETRO 500302 500104 LITL 517146 500547 500228 RELIANCE 532778 VIDEOIND TTNQY 532215 532540 AXISBANK RIGD YESBANK 532648 FLEXITUFF CDLYY PEL AXBKY 524075 PERSISTENT
The Indian benchmark indices are trading on a negative note this Monday afternoon with the Nifty50 trading at 11,466, down 122 points while the Sensex is trading lower by 382 points at 38,006.
500325 UBL DABUR BRTQY 511389 DBRQY 532478 USHAMART 500096 532483 BJJQY GODREJCP BRITANNIA 500493 BHARATFORG RLNIY SBAZ GICHSGFIN EXIDEIND BPCL AXB 524804 FSIC UHBTY UNITDSPR YYBKY 511676 ALBERTDA 517334 532424 JSWSTEEL CNRYY 532432 SANGHVIMOV AXBA EXQDY BAJFINANCE 533638 BRQPY UQNTY HINDPETRO 500104 LITL CANBK 507458 500825 517146 AUROPHARMA 500547 500228 RELIANCE IDBI 532778 VIDEOIND 532215 GDRJY MOZTY 532461 AXISBANK RIGD 500034 YESBANK UBNC SATIN 500116 UBHOLDINGS 532648 UNBWY FLEXITUFF 539404 AXBKY 524075 PNJZY MOTHERSUMI 530073 ARBQY PNB 500086
Most BDCs with higher exposure to oil-related investments have rebounded over the last two quarters partially due to rising oil prices and LIBOR resulting in higher book values and earnings.
AIY AINV GAIN HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD NMFC TSLF MCX HCAP CLA MCQ GAINM HRZN PNNT MCV GADDP CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA
The India benchmark indices continues to trade flat this Wednesday afternoon with the Nifty50 down 7 points at 11,731 while the Sensex is down 3 points at 38,893.
PWQFY 500325 532834 532514 511389 512599 532832 IGL TTKPRESTIG 532483 CAMLINFIN EICHERMOT CLNDY RLNIY SBAZ ANNRY AXB FSIC YYBKY 530005 JSWSTEEL CNRYY BRK.A AXBA BAJAJFINSV BATAINDIA TATASTEEL TATLY CANBK COALINDIA IBREALEST ADANIENT 500228 RELIANCE 532978 517506 VIDEOIND 532810 533278 532215 505200 500470 532187 532461 AXISBANK RIGD INDIACEM YESBANK UBNC ECQRY 517354 HVLQY INDUSINDBK 532648 AXBKY PFC TTST PNJZY HAVELLS PNB 500043
Shares of IL&FS Investment Managers will remain in focus, as the company will declare its first-quarter results of FY18. The company, a subsidiary of Infrastructure Leasing & Financial Services Limited (IL&FS), had reported a loss of ₹7.45 crore for the qurter ended March 2018 on revenues of ₹9.28 crore. For FY2018, net profit declined 83.44 per cent to ₹3.97 crore, against ₹23.97 crore reported during the previous fiscal.
570002 LICHSGFIN FSIC FRLDVR FRL 523574 LHFLY 500253
Due to the recent change in management, readers have asked if I could take a look at OCSI to determine whether operations have improved enough to currently justify an investment.
ACSF AIY AINV GAIN MCQ GAINM OAK MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX BLK NEWTL PBB
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET